CO68 Pooled Subgroup Analysis of Patient-Reported Outcomes at Week 52 Among Patients Achieving the Primary Endpoint of F-VASI75 at Week 24 in Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo
Abstract
Authors
K Ezzedine T Passeron J Seneschal D Rosmarin P Grimes JE Harris SR Desai M Lebwohl M Ruer-Mulard A Wolkerstorfer D Kornacki H Ren K Butler K Bibeau AG Pandya